What is the recommended evaluation and treatment for menstrual dysphoria in a reproductive‑age woman?

Evaluation and Treatment of Menstrual Dysphoria

Start selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacologic treatment for menstrual dysphoria (premenstrual dysphoric disorder), as they reduce premenstrual symptoms with moderate-certainty evidence, and consider luteal-phase-only dosing to minimize adverse effects while maintaining efficacy. 1

Diagnostic Confirmation

Before initiating treatment, confirm the diagnosis through prospective symptom tracking:

• Require at least two consecutive menstrual cycles of daily symptom charting to document that psychological and physical symptoms occur exclusively during the luteal phase (the two weeks before menstruation) and resolve within a few days after menses begins. 2, 3
• Rule out underlying psychiatric conditions such as major depressive disorder or generalized anxiety disorder, which persist throughout the cycle rather than remitting after menstruation. 4, 3
• Exclude pregnancy with a urine β-hCG test in all reproductive-age individuals presenting with menstrual-related symptoms. 5
• Screen for thyroid dysfunction with TSH measurement, as thyroid disorders can mimic or exacerbate premenstrual symptoms. 6

The distinction between premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) lies in severity: PMDD causes marked functional impairment in work, school, or relationships, whereas PMS symptoms are bothersome but do not significantly disrupt daily life. 2, 7

First-Line Pharmacologic Treatment: SSRIs

SSRIs are the evidence-based first-line pharmacologic treatment for PMDD, with fluoxetine, sertraline, and controlled-release paroxetine holding FDA approval for this indication. 8, 1

Dosing Strategies

• Luteal-phase-only administration (starting 14 days before expected menses and stopping at menstruation onset) is effective for most women with PMDD and reduces the total medication exposure and adverse effect burden compared to continuous dosing. 3, 8
• Continuous daily dosing produces a slightly larger symptom reduction (SMD -0.69 vs. -0.39 for luteal-phase dosing) and may be preferred for women with severe symptoms or those who also require treatment for comorbid depression or anxiety. 1
• Typical SSRI doses for PMDD are the same as those used for depression: fluoxetine 20 mg daily, sertraline 50–150 mg daily, or paroxetine CR 12.5–25 mg daily. 8

Expected Adverse Effects

SSRIs increase the risk of several dose-dependent adverse effects, and patients should be counseled about these before starting treatment:

• Nausea (OR 3.30; approximately 1 in 6 women will experience nausea attributable to the SSRI). 1
• Sexual dysfunction or decreased libido (OR 2.32). 1
• Insomnia (OR 1.99). 1
• Asthenia or decreased energy (OR 3.28). 1
• Somnolence and decreased concentration (OR 3.26). 1

Most adverse effects are mild to moderate and often diminish after the first few weeks of treatment. 8

Second-Line Treatment: Ovulation Suppression with Combined Hormonal Contraceptives

If SSRIs are ineffective, not tolerated, or contraindicated, suppress ovulation with continuous or extended-cycle combined oral contraceptives (COCs) containing 30–35 μg ethinyl estradiol. 4, 8

• Use monophasic formulations (e.g., ethinyl estradiol 30–35 μg with levonorgestrel or norgestimate) to provide stable hormone levels and prevent the luteal-phase hormonal fluctuations that trigger PMDD symptoms. 6
• Administer in extended or continuous regimens (active pills for 3–4 months followed by a 4–7 day hormone-free interval) to minimize the number of withdrawal bleeds and associated symptom flares. 6
• Counsel patients that breakthrough bleeding is common during the first 3–6 months of extended COC use but typically decreases with continued use and does not indicate treatment failure. 9, 6

Managing Breakthrough Bleeding on COCs

If unscheduled bleeding occurs during extended COC use:

• First-line intervention: NSAIDs (ibuprofen 400–600 mg three times daily or mefenamic acid 500 mg three times daily) for 5–7 days while continuing the COC. 9, 10
• Second-line option: Allow a planned 3–4 day hormone-free interval to induce withdrawal bleeding, but not during the first 21 days of the regimen and no more than once per month, as more frequent breaks reduce contraceptive efficacy. 9, 6

Contraindications to COCs

Do not prescribe COCs to women with:

• History of venous thromboembolism, stroke, or coronary artery disease. 6
• Uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg). 6
• Migraine with aura (due to increased stroke risk). 6
• Active or recent breast cancer. 6

Third-Line Treatment: GnRH Agonists with Add-Back Therapy

For women who fail both SSRIs and hormonal contraceptives, consider medical ovarian suppression with a GnRH agonist (e.g., leuprolide) plus estrogen-progestin add-back therapy to prevent hypoestrogenic adverse effects such as bone loss and vasomotor symptoms. 4, 8

This approach is reserved for severe, refractory PMDD because it induces a temporary menopause-like state and requires careful monitoring. 4

Adjunctive and Supportive Treatments

NSAIDs for Physical Symptoms

• Prescribe NSAIDs (ibuprofen 400–600 mg or naproxen 440–550 mg) during the luteal phase to reduce breast tenderness, bloating, and cramping. 8, 11

Lifestyle Modifications

• Recommend regular aerobic exercise (at least 30 minutes most days of the week), as it may reduce premenstrual symptoms, although the evidence is limited. 8
• Advise limiting caffeine and alcohol intake during the luteal phase, as both can exacerbate mood symptoms and breast tenderness. 8

Psychological Interventions

• Cognitive-behavioral therapy (CBT) and emotion-focused therapy (EFT) can reduce PMDD symptoms and improve emotion regulation, but access to trained therapists is often limited. 4, 12

Common Pitfalls and How to Avoid Them

• Do not diagnose PMDD based on retrospective recall alone, as women often overestimate symptom severity and fail to recognize symptoms that persist throughout the cycle. Always require prospective daily charting for at least two cycles. 3, 7
• Do not delay SSRI treatment while waiting for specialty referral or extensive workup, as effective therapy can be initiated in primary care once the diagnosis is confirmed. 3
• Do not prescribe progestin-only pills or copper IUDs for PMDD, as they do not suppress ovulation and may worsen mood symptoms. 6
• Do not use triphasic COCs for PMDD, as the varying hormone levels throughout the cycle can mimic the natural luteal-phase fluctuations that trigger symptoms. Use monophasic formulations instead. 6

Monitoring and Follow-Up

• Reassess symptom severity at 3 months after initiating SSRI or hormonal therapy to evaluate treatment response. 5
• If symptoms persist despite adequate trials of SSRIs and hormonal contraceptives, refer to a gynecologist or psychiatrist with expertise in PMDD for consideration of GnRH agonist therapy or other advanced interventions. 4, 8
• Monitor blood pressure at follow-up visits for patients on combined hormonal contraceptives. 6